Barclays Maintains RadNet(RDNT.US) With Buy Rating, Maintains Target Price $74
Truist Financial Maintains RadNet(RDNT.US) With Buy Rating, Cuts Target Price to $88
RadNet Is Maintained at Overweight by Barclays
Analysts' Top Healthcare Picks: Radnet (RDNT), Century Therapeutics (IPSC)
Barclays Maintains RadNet(RDNT.US) With Buy Rating, Cuts Target Price to $74
Barclays Keeps Their Buy Rating on Radnet (RDNT)
Raymond James Maintains RadNet(RDNT.US) With Buy Rating, Raises Target Price to $85
RadNet Analyst Ratings
Jefferies Maintains RadNet(RDNT.US) With Buy Rating, Maintains Target Price $80
Jefferies Maintains RadNet(RDNT.US) With Buy Rating, Cuts Target Price to $80
RadNet Is Maintained at Buy by Jefferies
RadNet Analyst Ratings
Jefferies Maintains RadNet(RDNT.US) With Buy Rating, Raises Target Price to $100
Barclays Maintains RadNet(RDNT.US) With Buy Rating, Raises Target Price to $85
RadNet Analyst Ratings
Truist Financial Maintains RadNet(RDNT.US) With Buy Rating, Announces Target Price $94
Truist Financial Sticks to Their Buy Rating for Radnet (RDNT)
Truist Raises Price Target on RadNet to $94 From $80, Keeps Buy Rating
Truist Financial Initiates RadNet(RDNT.US) With Buy Rating
Truist Financial Maintains RadNet(RDNT.US) With Buy Rating